Advocates are pushing back against Tricare's plan to end its coverage of weight-loss drugs for Tricare for Life beneficiaries ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older ...

Parsippany: Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. launch of a generic version of Saxenda ...

The drug, which is prescribed to around 90% of people in the UK using weight-loss injections, will see the cost of its ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

GLP-1 drugs may lower the risk of some obesity-related cancers, according to an observational study of people who were ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Investing.com -- Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) stock rose 2.7% after the company announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection), ...